What are the recommended diagnostic and therapeutic steps for managing Budd‑Chiari syndrome?

Management of Budd-Chiari Syndrome

All patients with Budd-Chiari syndrome should receive immediate and indefinite anticoagulation therapy unless major contraindications exist, followed by a stepwise escalation to interventional procedures (angioplasty/stenting or TIPS) if medical management fails, with liver transplantation reserved as salvage therapy. 1

Diagnostic Approach

Initial Imaging

• Doppler ultrasound is the first-line diagnostic test with sensitivity >75% for detecting hepatic venous outflow obstruction 1
• If ultrasound is inconclusive or an experienced sonographer is unavailable, proceed to MRI or CT for diagnostic confirmation 1
• Venography should be performed if diagnosis remains uncertain or to characterize anatomy before interventional treatment 1
• If large vessel obstruction is not demonstrated on imaging, liver biopsy can assess small hepatic vein thrombosis 1

Comprehensive Thrombophilia Workup

All BCS patients require extensive investigation for prothrombotic factors—finding one risk factor should not stop the search for additional causes 1:

• Inherited thrombophilias: Protein C, protein S, antithrombin levels, Factor V Leiden mutation, prothrombin G20210A gene variant 1
• Acquired thrombophilias: Anti-phospholipid antibodies (repeat after 12 weeks if positive) 1
• Myeloproliferative neoplasms: JAK2V617F mutation testing in all patients, even with normal blood counts 1
  • If JAK2V617F negative, perform calreticulin mutation screening 1
  • If both negative, consider bone marrow histology and refer to hematology 1
• Paroxysmal nocturnal hemoglobinuria screening 1
• Autoimmune disorders evaluation 1
• Local factors: Intra-abdominal inflammatory conditions and malignancies 1

Treatment Algorithm

Step 1: Medical Management (All Patients)

Anticoagulation is mandatory and should be initiated immediately 1:

• Start low molecular weight heparin (LMWH) for 5-7 days 1
• Simultaneously initiate vitamin K antagonist (VKA) targeting INR 2-3 1
• Continue LMWH until INR is therapeutic for two consecutive measurements 1
• Anticoagulation must be continued indefinitely to prevent clot extension and recurrent thrombosis 1

Portal hypertension complications are NOT contraindications to anticoagulation when adequately treated 1:

• Manage ascites and varices using the same protocols as cirrhotic patients 1
• Consider brief interruption of anticoagulation only for invasive procedures, including paracentesis 1

Treat underlying prothrombotic conditions concurrently 1:

• If myeloproliferative neoplasm identified: indefinite anticoagulation is required 1
• Consider anti-proliferative therapy (alpha interferon or hydroxyurea) to normalize blood counts 1
• For polycythemia vera: target hematocrit <45% 1

Step 2: Interventional Procedures (If Medical Management Fails)

Angioplasty/Stenting (First-Line Intervention) 1:

• Indicated for short hepatic vein stenosis or IVC stenosis 1
• Present in 60% of IVC obstruction cases and 25-30% of hepatic vein obstruction 1
• Particularly effective for segmental stenosis or "web" lesions common in Asian populations 2, 3
• Can be combined with local thrombolysis in recent, incomplete thrombosis 1

TIPS (Transjugular Intrahepatic Portosystemic Shunt) 1:

• Use PTFE-covered stents as the derivative treatment of choice 1
• Indicated when angioplasty/stenting is not feasible or fails 1
• Effective for long-segment thrombotic occlusion common in Western countries 2
• Technical success rate approximately 95% even with complete hepatic vein obliteration 2
• Five-year survival rate 90%, ten-year survival 80% 2

Surgical Shunting 1:

• Consider only when TIPS is not feasible or fails 1

Step 3: Liver Transplantation (Salvage Therapy)

Liver transplantation is indicated 1:

• When derivative techniques have failed 1
• For patients presenting with fulminant hepatic failure 1, 4
• Post-transplant survival outcomes are comparable to other indications, even in acute liver failure with multi-organ failure 4
• Anticoagulation must be continued after transplantation in most patients 1

Critical Management Points

Referral and Monitoring

• Refer all BCS patients to expert centers immediately 1
• Closely monitor for early detection of liver deterioration to guide escalation of therapy 1
• Screen for hepatocellular carcinoma, though distinguishing benign from malignant nodules is difficult and may require specialized centers 1

Common Pitfalls to Avoid

• Do not delay anticoagulation while awaiting complete thrombophilia workup 1
• Do not withhold anticoagulation due to varices or ascites if portal hypertension is adequately managed 1
• Do not stop searching after finding one prothrombotic factor—multiple risk factors frequently coexist 1
• The traditional stepwise approach waiting for medical failure before intervention is increasingly questioned; some experts advocate earlier interventional treatment when portal hypertension signs appear to prevent hepatic fibrosis progression 5

Special Considerations

• Pregnancy is not contraindicated in BCS patients, with favorable maternal outcomes, though fetal outcomes remain poor 4
• Bleeding complications on anticoagulation have decreased from 50% to 17% with better procedural management and portal hypertension prophylaxis 1
• Most patients require lifelong anticoagulation regardless of treatment modality 4